DSM, a global leader in biomedical materials science, today announced that the company has signed a license and supply agreement with spinal implant and surgical systems developer, SpineVision.
The agreement grants SpineVision® the use of Bionate® II PCU, a proprietary DSM polymer, in its new Flex±2™ system. The system is adaptable to the various stages of disc degeneration from early degeneration of intervertebral discs to total disc degeneration requiring fusion procedures. This level of flexibility not only offers spine surgeons more options in the treatment of lumbar disc diseases, but also allows selective segmental stabilization to better treat disc degeneration throughout multiple stages.
The Flex+2™ system utilizes a top-loading, top-tightening design, which accommodates both open and percutaneous approaches. DSM’s Bionate® II PCU encapsulates the metal wire and provides the system with enhanced frontal and sagittal stabilization, assuring flexion and extension, which allow for increased freedom of movement and better accommodation to the spine without loss of strength or stability.
“The combination of design changes and the use of Bionate® II PCU have enabled SpineVision® to enhance the mechanical capabilities of the new Flex+2TM system leading to extended indications” said Arnaud Brisard, Chief Executive Officer, SpineVision®.
“DSM’s polyurethane materials have a proven clinical history and have been used in several dynamic stabilization devices and implants,” said William Fuller, Director of Business Development, DSM Biomedical. “Our Bionate® II PCU provides increased flexibility and shock absorbing characteristics, replicating the natural movements of the spine. We are proud to see Bionate® II PCU contributing to the performance of SpineVision’s Flex+2™ system.”
SpineVision® will initially launch the Flex+2™ system in the European Union. The device is not currently available for sale in the U.S.